skip to Main Content

Ipreo Quarterly US Update: Quarter Ending December 31, 2016

In total, Q4 saw 184 deals for $48.8B in proceeds, slightly below of Q3’s 191 deals for $65.0B in proceeds. However, the quarter outpaced the 129 deals for $43.0B seen in prior-year period. Separately, the quarter’s IPO deal count increased to 25 for $7.2B in proceeds, just above (in terms in proceeds) the prior quarter’s 26 deals and $5.9B in proceeds. Finally, Q4 follow-ons and block trades accounted for 141 of the total deals for the quarter and generated $36.4B.

Ipreo Quarterly US Update: Quarter Ending September 30, 2016

In total, Q3 saw 191 deals for $65.0B in proceeds, slightly ahead of Q2’s 182 deals for $55.2B in proceeds; additionally, the quarter outperformed the 154 deals for $38.3B seen in Q3 2015. Separately, the quarter’s IPO deal count increased to 31 for $6.2B in proceeds, just above the prior quarter’s 26 deals and $5.9B in proceeds. Finally, Q3 follow-ons and block trades accounted for 133 of the total deals for the quarter and generated $43.7B.

Ipreo Quarterly US Update: Quarter Ending June 30, 2016

The second quarter of 2016 saw a total of 182 deals come to market for proceeds of $55.2B, an uptick from the first quarter’s 108 deals for $40.7B but a significant decline from the prior-year period’s 276 deals for $80.9B. Furthermore, the second quarter saw a sizable jump in IPO as 26 new issuers made their market debuts and generated $5.9B in proceeds, following a dismal first quarter in which just 6 issuers made their public debuts for $569.6M.

Ipreo Quarterly US Update: Quarter Ending March 31, 2016

The new issuance market began the year down on proceeds and deals count from the prior quarter. In total, Q1 saw 108 deals for $40.7B in proceeds, less than Q4’s 129 deals for $43.0B. Also, the quarter paled in comparison to the 265 deals for $90.5B seen in Q1 2015.  Furthermore, the quarter’s IPO deal count fell to 6 for $569.6M in proceeds, well below the prior-year period’s 31 deals for $5.6B.

Ipreo Quarterly US Update: Quarter ending September 30, 2015

Healthcare, once again, proved to be a dominant force for new issuance in Q3 2015, contributing 64 deals for a total of $10.2B in proceeds and accounting for over a third of the quarter’s volume. In the past, we have continually referenced the impressive streak the sector is on, but within this piece we take a closer look at Healthcare deals since 2005 to frame the rise of the sector in today’s market.
Back To Top